Pharmaceutical Research

, Volume 24, Issue 5, pp 1014–1025

AAPS-FDA Workshop White Paper: Microdialysis Principles, Application and Regulatory Perspectives

  • Chandra S. Chaurasia
  • Markus Müller
  • Edward D. Bashaw
  • Eva Benfeldt
  • Jan Bolinder
  • Ross Bullock
  • Peter M. Bungay
  • Elizabeth C. M. DeLange
  • Hartmut Derendorf
  • William F. Elmquist
  • Margareta Hammarlund-Udenaes
  • Christian Joukhadar
  • Dean L. KelloggJr.
  • Craig E. Lunte
  • Carl Henrik Nordstrom
  • Hans Rollema
  • Ronald J. Sawchuk
  • Belinda W. Y. Cheung
  • Vinod P. Shah
  • Lars Stahle
  • Urban Ungerstedt
  • Devin F. Welty
  • Helen Yeo
Research Paper

DOI: 10.1007/s11095-006-9206-z

Cite this article as:
Chaurasia, C.S., Müller, M., Bashaw, E.D. et al. Pharm Res (2007) 24: 1014. doi:10.1007/s11095-006-9206-z

Abstract

Many decisions in drug development and medical practice are based on measuring blood concentrations of endogenous and exogenous molecules. Yet most biochemical and pharmacological events take place in the tissues. Also, most drugs with few notable exceptions exert their effects not within the bloodstream, but in defined target tissues into which drugs have to distribute from the central compartment. Assessing tissue drug chemistry has, thus, for long been viewed as a more rational way to provide clinically meaningful data rather than gaining information from blood samples. More specifically, it is often the extracellular (interstitial) tissue space that is most closely related to the site of action (biophase) of the drug. Currently microdialysis (μD) is the only tool available that explicitly provides data on the extracellular space. Although μD as a preclinical and clinical tool has been available for two decades, there is still uncertainty about the use of μD in drug research and development, both from a methodological and a regulatory point of view. In an attempt to reduce this uncertainty and to provide an overview of the principles and applications of μD in preclinical and clinical settings, an AAPS-FDA workshop took place in November 2005 in Nashville, TN, USA. Stakeholders from academia, industry and regulatory agencies presented their views on μD as a tool in drug research and development.

Key words

clinical pharmacologymicrodialysisrecoveryregulatory aspects

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Chandra S. Chaurasia
    • 1
  • Markus Müller
    • 2
  • Edward D. Bashaw
    • 3
  • Eva Benfeldt
    • 4
  • Jan Bolinder
    • 5
  • Ross Bullock
    • 6
  • Peter M. Bungay
    • 7
  • Elizabeth C. M. DeLange
    • 8
  • Hartmut Derendorf
    • 9
  • William F. Elmquist
    • 10
  • Margareta Hammarlund-Udenaes
    • 11
  • Christian Joukhadar
    • 2
  • Dean L. KelloggJr.
    • 12
  • Craig E. Lunte
    • 13
  • Carl Henrik Nordstrom
    • 14
  • Hans Rollema
    • 15
  • Ronald J. Sawchuk
    • 10
  • Belinda W. Y. Cheung
    • 10
  • Vinod P. Shah
    • 16
  • Lars Stahle
    • 17
  • Urban Ungerstedt
    • 18
  • Devin F. Welty
    • 19
  • Helen Yeo
    • 20
  1. 1.Division of BioequivalenceOffice of Generic Drugs, Food and Drug AdministrationRockvilleUSA
  2. 2.Department of Clinical PharmacologyMedical University ViennaViennaAustria
  3. 3.Division of Clinical Pharmacology III, Office of Clinical PharmacologyUS-FDASilver SpringUSA
  4. 4.Department of DermatologyUniversity of CopenhagenCopenhagenDenmark
  5. 5.Deptartment of MedicineKarolinska University Hospital Huddinge, Karolinska InstitutetStockholmSweden
  6. 6.Medical College of VirginiaRichmondUSA
  7. 7.Division of Bioengineering and Physical ScienceOffice of Research Services, NIHBethesdaUSA
  8. 8.LACDRLeidenThe Netherlands
  9. 9.Department of PharmaceuticsUniversity of FloridaGainesvilleUSA
  10. 10.Department of PharmaceuticsUniversity of MinnesotaMinneapolisUSA
  11. 11.Department of Pharmaceutical BiosciencesUppsala UniversityUppsalaSweden
  12. 12.Department of MedicineThe University of Texas Health Science Center at San AntonioSan AntonioUSA
  13. 13.Department of ChemistryUniversity of KansasLawrenceUSA
  14. 14.Department of NeurosurgeryUniversity HospitalLundSweden
  15. 15.Department NeurosciencePfizer Global ResearchGrotonUSA
  16. 16.Pharmaceutical FederationNorth PotomacUSA
  17. 17.Astra ZenecaSödertäljeSweden
  18. 18.Department of Physiology and PharmacologyKarolinska InstitutetStockholmSweden
  19. 19.Pharmacokinetics and Drug MetabolismAllergan Inc.IrvineUSA
  20. 20.Departnment of Drug Metabolism and PharmacokineticsRoche Palo AltoUSA